Physician profile
Rajeev Gupta
NPI 1669602603
$1,638.18
in general payments reported to CMS, 2019-2025
20 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $474 · 2021: $116 · 2022: $128 · 2023: $41.05 · 2024: $34.10 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $251.89 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $631.91 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.81 | 2019-2025 | Ofev, Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2020 | |
| Glaxosmithkline, LLC. | $110.10 | 2019-2020 | |
| Grifols USA, LLC | $86.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $76.35 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $55.32 | 2019-2025 | Fasenra |
| Mallinckrodt Hospital Products INC. | $54.86 | 2021-2024 | Terlivaz |
| Fisher & Paykel Healthcare INC | $47.18 | 2020 | |
| Sunovion Pharmaceuticals INC. | $39.45 | 2019-2020 | |
| Genentech USA, INC. | $38.74 | 2019 | |
| Amgen INC. | $38.34 | 2025 | Tezspire |
| La Jolla Pharmaceutical Company | $32.45 | 2019 | |
| Veran Medical Technologies, INC. | $30.73 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $25.60 | 2025 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $25.01 | 2025 | Ohtuvayre |
| Portola Pharmaceuticals, LLC | $21.01 | 2019 | |
| Insmed, INC. | $18.06 | 2025 | Brinsupri, Arikayce |
| Pulmonx Corporation | $17.85 | 2020 | |
| Mylan Specialty L.P. | $16.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.